# US 2022/0031738 A1 · Iron formulations for topical administration and methods of treatment of iron deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031738 A1
- Document ID: US20220031738A1
- Status: Published application
- Kind: A1
- Application number: 17/282,991
- Filed: 2019-10-05
- Published: 2022-02-03
- Earliest claimed: 2018-10-05
- Assignees: Dyve Biosciences, Inc.
- Applicants: Dyve Biosciences, Inc.
- Inventors: Ryan Beal; Luke Gonzales; Kilmar Martinez; Brandon Sand; Lisa Misell; Nathan Fitzsimmons
- Web page: https://patentgrep.com/patent/US20220031738A1

## CPC

- A61K 33/26: Iron; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K 47/547: {Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent}
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 7/06: Antianaemics
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are formulations for the transdermal administration of iron or an iron containing compound. Also provided are formulations that include iron chelators and antioxidants, and methods of using the formulations provided herein for the treatment of diseases and disorders relating to iron deficiency, anemia, and conditions associated with anemia.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A formulation for transdermal delivery of one or more iron-containing compounds through the skin of a subject, the formulation comprising:
an iron-containing compound;
an iron chelator;
an antioxidant; and
one or more of the following:
almond oil, Cetiol® Ultimate, cetyl alcohol, citric acid, cyclohexane, Durosoft, glacial acetic acid, H2O, HP beta-CD, lecithin, Phospholipon® 90G, Poloxamer 407, propanoic acid, stearic acid, Tego 13-06, titanium dioxide, and triacetin.

### Claim 22 (depends on 21)

The formulation of claim 21, wherein the iron chelator is one or more of:
ethylenediaminetetraacetic acid (EDTA), deferoxamine, 1,2-diethyl-3-hydroxypyridin-4-one (CP94), Desferol, Deferiprone and Deferasirox, succimer, trientine, Desferrithiocin, Clioquinol, 0-trensox, Tachpyr, Dexrazoxane, Triapine, Pyridoxal isonicotinoyl hydrazone, Di-2-pyridylketone thiosemicarbazone series, Flavan-3-ol, Curcumin, Apocynin, Kolaviron, Floranol, Baicalein, Baicalin, ligustrazine, Quercetin, Epigallocatechin gallate, Theaflavin, Phytic acid, and Genistein.

### Claim 23 (depends on 22)

The formulation of claim 22, wherein the iron chelator is EDTA.

### Claim 24 (depends on 21)

The formulation of claim 21, wherein the antioxidant is one or more of:
vitamin C, vitamin E, glutathione, superoxide dismutase, catalase, pNaKtide, Butylated hydroxytoluene, Butylated hydroxyanisole, tert-Butylhydroquinone, HP beta CD, resveratrol, retinol, coenzyme q10, niacinamide, polyphenols, flavenoids, beta-carotene, lutein, and lycopene.

### Claim 25 (depends on 24)

The formulation of claim 24, wherein the antioxidant is vitamin C and/or vitamin E.

### Claim 26 (depends on 21)

The formulation of claim 21, wherein the formulation comprises two or more of, three or more of, four or more of, five or more of, six or more of, seven or more of, eight or more of, nine or more of, ten or more of, eleven or more of, twelve or more of, thirteen or more of, fourteen or more of, fifteen or more of, or sixteen or more, or seventeen of:
almond oil, Cetiol® Ultimate, cetyl alcohol, citric acid, cyclohexane, Durosoft, glacial acetic acid, H2O, HP beta-CD, lecithin, Phospholipon® 90G, Poloxamer 407, propanoic acid, stearic acid, Tego 13-06, titanium dioxide, and triacetin.

### Claim 27 (depends on 26)

The formulation of claim 26, wherein when included in the formulation:
Phospholipon® 90G is present in an amount from about 5.0% w/w to about 15.0% w/w;
cetyl alcohol is present in an amount from about 1.0% w/w to about 5.0% w/w;
stearic acid is present in an amount from about 0.5% w/w to about 5.0% w/w;
triacetin is present in an amount from about 5.0% w/w to about 25.0% w/w;
lecithin is present in an amount from about 1.0% w/w to about 10.0% w/w;
almond oil is present in an amount from about 3% w/w to about 15.0% w/w;
Cetiol® Ultimate is present in an amount from about 3.0% w/w to about 20.0% w/w;
Poloxamer 407 is present in an amount from about 2.0% w/w to about 20.0% w/w;
glacial acetic acid is present in an amount from about 2.0% w/w to about 10.0% w/w;
propanoic acid is present in an amount from about 1.0% w/w to about 5.0% w/w;
cyclohexane is present in an amount from about 2.0% w/w to about 10.0% w/w;
Tego 13-06 is present in an amount from about 2.0% w/w to about 10.0% w/w;
Durosoft® PK-SG is present in an amount from about 0.5% w/w to about 3.0% w/w;
HP beta CD is present in an amount up to about 1.0% w/w;
citric acid is present in an amount up to about 5.0% w/w; and
titanium dioxide is present in an amount up to about 5.0% w/w.

### Claim 28 (depends on 21)

The formulation of claim 21, wherein the iron-containing compound is selected from ferrous sulfate, sucrosomial iron, polysaccharide iron complex, ferrous fumarate, ferrous gluconate, ferric carboxymaltose, ferumoxytol, iron isomaltoside 1000, ferric gluconate, iron sucrose, and ferric pyrophosphate.

### Claim 29 (depends on 28)

The formulation of claim 28, wherein the iron-containing compound comprises ferrous sulfate.

### Claim 30 (depends on 29)

The formulation of claim 29, wherein the ferrous sulfate is present in the formulation in an amount from about 3.0% to about 40.0% w/w.

### Claim 31 (depends on 29)

The formulation of claim 29, wherein the ferrous sulfate is present in the formulation in an amount from about 3.0% w/w to about 15.0% w/w.

### Claim 32 (depends on 29)

The formulation of claim 29, wherein the ferrous sulfate is present in the formulation in an amount of about 6.0% w/w.

### Claim 33 (depends on 29)

The formulation of claim 29, wherein the ferrous sulfate is present in particles narrower than about 10 nm.

### Claim 34 (depends on 29)

The formulation of claim 29, wherein the ferrous sulfate is present in particles narrower than about 1 μm in diameter.

### Claim 35 (depends on 29)

The formulation of claim 29, wherein the ferrous sulfate is present in particles of about 50 μm in diameter.

### Claim 36 (depends on 21)

A method of treating an iron deficiency or related disorder in a subject in need thereof, the method comprising administering an effective amount of a formulation according to claim 21 to the subject,
wherein the effective amount of the formulation improves or treats the iron deficiency or the related disorder.

### Claim 37 (depends on 36)

The method of claim 36, wherein the iron deficiency or related disorder is an anemia that is associated with: a sickle cell disease; a bleeding disorder; an iron deficiency; aging; a hematological disease or disorder; a blood cancer; a cancer; or with inflammatory bowel disease.

### Claim 38 (depends on 36)

The method of claim 36, wherein the subject in need thereof is a non-hemodialysis patient with chronic kidney disease, a patient with progressive renal insufficiency, a pregnant woman having or susceptible to having anemia, or in a subject having iron depletion associated with athletic training.

### Claim 39

A formulation for transdermal delivery of one or more iron containing compounds through the skin of a subject, comprising:
an iron containing compound comprising ferrous sulfate in an amount from about 3.0% to about 40.0% w/w;
Phospholipon® 90G in an amount from about 5.0% w/w to about 15.0% w/w;
cetyl alcohol in an amount from about 1.0% w/w to about 5.0% w/w;
stearic acid in an amount from about 0.5% w/w to about 5.0% w/w;
triacetin in an amount from about 5.0% w/w to about 25.0% w/w;
lecithin in an amount from about 1.0% w/w to about 10.0% w/w;
almond oil in an amount from about 3% w/w to about 15.0% w/w;
Cetiol® Ultimate in an amount from about 3.0% w/w to about 20.0% w/w;
Poloxamer 407 in an amount from about 2.0% w/w to about 20.0% w/w;
glacial acetic acid in an amount from about 2.0% w/w to about 10.0% w/w;
propanoic acid in an amount from about 1.0% w/w to about 5.0% w/w;
cyclohexane in an amount from about 2.0% w/w to about 10.0% w/w;
Tego 13-06 in an amount from about 2.0% w/w to about 10.0% w/w;
Durosoft® PK-SG in an amount from about 0.5% w/w to about 3.0% w/w; and
H2O to complete; and
optionally comprising one or more of
HP beta CD in an amount up to about 1.0% w/w;
citric acid in an amount up to about 5.0% w/w;
vitamin C in an amount up to about 5.0% w/w;
vitamin E in an amount up to about 5.0% w/w;
EDTA in an amount up to about 20.0% w/w; and
titanium dioxide in an amount up to about 5.0% w/w.

### Claim 40

A formulation for transdermal delivery of one or more iron containing compounds through the skin of a subject, comprising:
an iron containing compound comprising ferrous sulfate in an amount from about 3.0% to about 40.0% w/w; Phospholipon® 90G in an amount from about 0.0% to about 15.0% w/w; cetyl alcohol in an amount from about 0.0% to about 5.0% w/w; stearic acid in an amount from about 0.0% to about 5.0% w/w; triacetin in an amount from about 0.0% to about 40.0% w/w; lecithin in an amount from about 0.0% to about 10.0% w/w; almond oil in an amount from about 0.0% to about 15.0% w/w; Cetiol® Ultimate in an amount from about 0.0% to about 20.0% w/w; Poloxamer 407 in an amount of from about 0.0% to about 20.0% w/w; glacial acetic acid in an amount from about 0.0% to about 10.0% w/w; propanoic acid in an amount from about 0.0% to about 5.0% w/w; cyclohexane in an amount from about 0.0% to about 10.0% w/w; tego 13-06 in an amount from about 0.0% to about 10.0% w/w; Durosoft® PK-SG in an amount from about 0.0% to about 3.0% w/w; HP beta CD in an amount from about 0.0% to about 1.0% w/w; citric acid in an amount from about 0.0% to about 5.0% w/w; vitamin C in an amount from about 0.0% to about 5.0% w/w; vitamin E in an amount from about 0.0% to about 5.0% w/w; EDTA in an amount from about 0.0% to about 20.0% w/w; titanium dioxide in an amount from about 0.0% to about 5.0% w/w; and water to complete.
